Last CNY54.29 CNY
Change Today +0.29 / 0.54%
Volume 962.7K
002437 On Other Exchanges
Symbol
Exchange
Shenzhen
As of 3:00 AM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

harbin gloria pharmaceutic-a (002437) Snapshot

Open
CNY54.00
Previous Close
CNY54.00
Day High
CNY54.57
Day Low
CNY53.35
52 Week High
07/9/14 - CNY60.50
52 Week Low
07/29/13 - CNY25.08
Market Cap
15.2B
Average Volume 10 Days
2.6M
EPS TTM
CNY0.98
Shares Outstanding
280.0M
EX-Date
07/4/14
P/E TM
55.6x
Dividend
CNY0.10
Dividend Yield
0.18%
Current Stock Chart for HARBIN GLORIA PHARMACEUTIC-A (002437)

Related News

No related news articles were found.

harbin gloria pharmaceutic-a (002437) Related Businessweek News

No Related Businessweek News Found

harbin gloria pharmaceutic-a (002437) Details

Harbin Gloria Pharmaceuticals Co., Ltd. is engaged in the research, development, production, and sale of pharmaceutical products primarily in the People’s Republic of China. The company offers orthopedic medicines, antineoplastics, nutrition products, rheumatology drugs, digestive and respiratory system medicines, cardiovascular medicines, liver disease medications, gynecology medications, and antibiotics. It also provides circulatory system, pediatrics, uropoiesis and reproduction, immune regulation, and other products. Harbin Gloria Pharmaceuticals Co., Ltd. was founded in 2000 and is based in Harbin, the People’s Republic of China.

Founded in 2000

harbin gloria pharmaceutic-a (002437) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

harbin gloria pharmaceutic-a (002437) Key Developments

Harbin Gloria Pharmaceuticals Co., Ltd Announces 2013 Final Distribution Plan, Payable on July 04, 2014

Harbin Gloria Pharmaceuticals Co. Ltd. announced 2013 final distribution plan to be implemented (A shares) of cash dividend per 10 shares (tax included) of CNY 1.00000000. The dividend is payable on 04 July 2014, to the shareholders with the record date of 03 July 2014. The ex-date is 04 July 2014. Tax on cash dividend per 10 shares of CNY 0.10000000 (10% x CNY 1.00000000). Net cash dividend per 10 shares after tax of CNY 0.90000000 (CNY 1.00000000 - CNY 0.10000000).

Harbin Gloria Pharmaceuticals Co., Ltd Approves 2013 Profit Distribution Plan

Harbin Gloria Pharmaceuticals Co. Ltd. at its AGM held on May 12, 2014, approved cash dividend (tax included) of CNY 1.00000000 per 10 shares for the year 2013.

Cumberland Pharmaceuticals and Gloria Pharmaceuticals Announce Joint Research & Development Investment

Cumberland Pharmaceuticals Inc.and China's Gloria Pharmaceuticals Co. announced a joint research & development initiative. Each company has made a $1 million investment in Cumberland Emerging Technologies (CET), which is majority owned by Cumberland and partners with academic research centers to develop promising biopharmaceutical technologies. The new funds will be used to accelerate development of CET's pipeline of new product candidates emerging from Vanderbilt University and other regional research centers. CET was established among Cumberland Pharmaceuticals, Vanderbilt University and the state of Tennessee to support the development of biopharmaceutical product candidates. Gloria will have the first opportunity to negotiate a license to CET products for China, and Cumberland will retain access to CET's product rights for the rest of the world.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002437:CH CNY54.29 CNY +0.29

002437 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002437.
View Industry Companies
 

Industry Analysis

002437

Industry Average

Valuation 002437 Industry Range
Price/Earnings 57.2x
Price/Sales 11.2x
Price/Book 6.4x
Price/Cash Flow 57.4x
TEV/Sales 10.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HARBIN GLORIA PHARMACEUTIC-A, please visit www.gloria.cc. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.